A viral kinetic study using pegylated interferon alfa‐2b and/or lamivudine in patients with chronic hepatitis B/HBeAg negative
Vassiliki‐Anastasia Sypsa, Konstantinos Mimidis, Nicholas C. Tassopoulos, Dimitrios Chrysagis, Themistoklis Vassiliadis, Antonios Moulakakis, Maria Raptopoulou, Caterina Haida, Angelos Hatzakis – 16 June 2005 – We studied viral dynamic parameters in 44 chronic hepatitis B/hepatitis B e antigen (HBeAg)(−) patients treated with pegylated interferon alfa‐2b (PEG‐IFN) 100 or 200 μg weekly or lamivudine 100 mg daily or the combination of PEG‐IFN 100 or 200 μg with lamivudine.